https://www.biospace.com/partnered Partnered en-US Tue, 30 Jun 2026 17:54:36 GMT https://www.biospace.com/press-releases/tempramed-expands-strategic-partnership-with-mckesson-medical-surgical-to-accelerate-north-american-growth-and-launch-full-portfolio-across-b2b-channels Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer base Tue, 30 Jun 2026 17:54:36 GMT https://www.biospace.com/press-releases/tempramed-expands-strategic-partnership-with-mckesson-medical-surgical-to-accelerate-north-american-growth-and-launch-full-portfolio-across-b2b-channels https://www.biospace.com/press-releases/luxna-biotech-and-biospring-extend-strategic-xna-partnership-to-include-guna-amidites-in-biosprings-oligonucleotide-manufacturing-services Key Highlights: · Luxna and BioSpring have extended their existing agreement, enabling the manufacture of next-generation oligonucleotides incorporating Luxna’s GuNA™ amidites, in addition to AmNA™, scpBNA™, and 5′-CP™. · GuNA™ further expands the range of Luxna’s proprietary Xeno Nucleic Acid (XNA) chemistries already available through BioSpring’s oligonucleotide manufacturing services. · GuNA™-modified oligonucleotides are designed to provide enhanced nuclease resistance, improved target binding, reduced immunotoxicity and neurotoxicity; properties that provide key advantages for developing better efficacy and safer therapies targeting neurodegenerative diseases. Thu, 18 Jun 2026 13:10:53 GMT https://www.biospace.com/press-releases/luxna-biotech-and-biospring-extend-strategic-xna-partnership-to-include-guna-amidites-in-biosprings-oligonucleotide-manufacturing-services https://www.biospace.com/business/the-commercial-launch-playbook-team-structure-readiness-and-execution Jennifer C. Smith-Parker Intellia Therapeutics's Senior Vice President Maria Natale discusses why the most successful launches are shaped long before approval, with strategy, structure and patient insight at the core. Mon, 15 Jun 2026 07:00:00 GMT https://www.biospace.com/business/the-commercial-launch-playbook-team-structure-readiness-and-execution https://www.biospace.com/drug-delivery/lotte-biologics-tightens-global-quality-as-syracuse-adc-hub-ramps-for-2026 Jennifer C. Smith-Parker BioSpace Insights With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance. Mon, 19 Jan 2026 08:01:00 GMT https://www.biospace.com/drug-delivery/lotte-biologics-tightens-global-quality-as-syracuse-adc-hub-ramps-for-2026 https://www.biospace.com/press-releases/l7-informatics-and-turnberry-solutions-announce-strategic-teaming-agreement-to-accelerate-life-sciences-innovation-at-enterprise-scale Collaboration combines AI-ready data platforms with delivery certainty to help life sciences and food companies move faster, from strategy to measurable outcomes. Thu, 08 Jan 2026 17:59:10 GMT https://www.biospace.com/press-releases/l7-informatics-and-turnberry-solutions-announce-strategic-teaming-agreement-to-accelerate-life-sciences-innovation-at-enterprise-scale https://www.biospace.com/drug-development/takedas-commitment-to-trial-representation-is-shaping-the-future-of-clinical-research BioSpace Insights One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future. Mon, 05 Jan 2026 05:01:00 GMT https://www.biospace.com/drug-development/takedas-commitment-to-trial-representation-is-shaping-the-future-of-clinical-research https://www.biospace.com/press-releases/cibus-therapeutics-announces-strategic-partnership-with-mission-cure-and-greenstone-biosciences-to-accelerate-development-of-cbt-101-a-novel-therapy-for-chronic-pancreatitis Fri, 19 Dec 2025 15:11:38 GMT https://www.biospace.com/press-releases/cibus-therapeutics-announces-strategic-partnership-with-mission-cure-and-greenstone-biosciences-to-accelerate-development-of-cbt-101-a-novel-therapy-for-chronic-pancreatitis https://www.biospace.com/press-releases/maxwell-biosciences-subsidiary-havih-announces-partnership-with-the-government-of-andhra-pradesh This partnership will establish a new research and production facility in Andhra Pradesh, driving India's transition toward pharmaceutical leadership and creating high-tech jobs Thu, 18 Dec 2025 14:16:53 GMT https://www.biospace.com/press-releases/maxwell-biosciences-subsidiary-havih-announces-partnership-with-the-government-of-andhra-pradesh https://www.biospace.com/drug-delivery/bridging-formulation-and-device-integrated-supply-chain-strategies-for-u-s-pharma-manufacturing Jennifer C. Smith-Parker BioSpace Insights The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts. Mon, 08 Dec 2025 11:00:00 GMT https://www.biospace.com/drug-delivery/bridging-formulation-and-device-integrated-supply-chain-strategies-for-u-s-pharma-manufacturing https://www.biospace.com/drug-development/building-the-next-generation-of-biologics-inside-the-future-of-protein-engineering BioSpace Insights As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new bottleneck: engineering and producing molecules whose complexity challenges conventional workflows. Mon, 01 Dec 2025 11:21:08 GMT https://www.biospace.com/drug-development/building-the-next-generation-of-biologics-inside-the-future-of-protein-engineering